Drugs / Borneol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03495206 | Oct 2018 → Dec 2020 | stroke disorder | Yantai YenePharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05901532 | Nov 2020 → Apr 2022 | allergic rhinitis | Taichung Veterans General Hospital | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07604350 | Jun 2026 → Jun 2030 expected | epilepsy | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Borneol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05901532 ↗ |
| Route | Other | “The drug will be administered as one tablet sublingually twice daily” NCT07604350 ↗ |